Seeking Alpha

Fusion Pharmaceuticals Announces IND Clearance for FPI-2068, a Jointly Developed Novel Targeted Alpha Therapy

HAMILTON, ON and BOSTON, April 12, 2023 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision ...
Seeking Alpha

Fusion Pharmaceuticals Announces Presentation of Preclinical Data Supporting FPI-2059 and Leading Targeted Alpha Therapy Platform at AACR Annual Meeting

HAMILTON, ON and BOSTON, April 19, 2023 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as ...